
Provisional Applications in the time of Covid-19.

A collective effort is being made by big corporations, start-ups and individuals to tackle the Covid-19 disease. Some companies are doing research & development to diagnose infected patients, while others are developing vaccines or drugs to treat the virus. But along with the ongoing work it is also important to secure the innovative solutions in the form of patents, especially for start-ups and universities. Filing patents for the solutions of Covid-19 at the moment could be a great strategy for companies in the long run and a potential source of revenue in the future. Companies with limited budgets can start securing their innovations with **provisional filings**. Recent filings related to Covid-19 solutions are listed below.

COMPANY NAME	BRIEF
<p>Enzychem Lifesciences¹</p> <p><i>A company with focus on developing new drugs and APIs (Active Pharmaceutical Ingredients).</i></p> <p>Seoul, South Korea</p>	<p>The company has filed a provisional patent application with the US patent office to cover treating COVID-19 with its leading compound EC-18.</p> <p>EC-18 is a drug that resolves inflammation by allowing complete viral clearance while minimizing tissue damage. It quickly neutralizes SARS-CoV-2, by preventing cytokine storm or acute respiratory distress syndrome (ARDS), based on its mechanism of action.</p>
<p>NellOne Therapeutics²</p> <p><i>A biopharmaceutical company that develops regenerative medicine using its leading protein, the company has been spun out of the U.S. Department of Energy's Oak Ridge National Laboratory in Oak Ridge.</i></p> <p>Oak Ridge, TN</p>	<p>NellOne files a provisional patent application titled as, “Methods and Compositions for Treating Tissue Damage Resulting from Viral Infections”, the application focuses around the usage of the NELL1 signaling protein in the treatment of respiratory viral infections including COVID-19. The application details related to the treatment and</p>

	prevention of tissue damage and inflammation resulting from COVID-19 or other respiratory viral infections.
<p>Predictmedix Inc³</p> <p><i>An artificial intelligence company with focus on impairment detection and healthcare screening.</i></p> <p>Toronto, Canada</p>	<p>Toronto-based company has filed a patent application with the USPTO having an App No 63012510 – Artificial Intelligence driven rapid screening system for infectious diseases, such as SARS-CoV-2 virus responsible for COVID-19.</p>
<p>Polyrizon⁴</p> <p><i>A company that develops novel biological-gels based on its novel C&C (capture and contain) platform technology.</i></p> <p>Ofakim, Israel</p>	<p>The company has filed a US Patent Application for Formulations and Methods for Preventing Viral Infections by COVID-19 Virus.</p>
<p>Anna University⁵</p> <p><i>A public state University that provides high-quality education in the fields of technology, engineering, applied sciences and architecture.</i></p> <p>Chennai, India</p>	<p>This university filed a patent application to cover its novel sanitizer to destroy genetic material of COVID-19. The novel and enhanced sanitizer not only eliminates the proteins and lipids (outer envelope) of the Corona virus, but also its genetic material (nucleic acid).</p>
<p>Synact Pharma⁶</p> <p><i>A biotech company with focus on fighting inflammatory and auto-immune diseases.</i></p> <p>Lund, Sweden</p>	<p>The company has applied for a patent application with the EPO For Ap1189 to treat COVID-19 infection. The use of Ap1189 investigates anti-inflammatory drug candidate AP1189 as adjunctive therapy in patients with covid-19 infection to prevent ARDS.</p>
<p>The Israel Institute for Biological Research⁷</p> <p><i>The Israeli's government research Centre that works in the fields of biology, chemistry,</i></p>	<p>The Israel Institute for Biological Research (IIBR) has filed 8 patent requests for eight types of coronavirus antibodies.</p> <p>The institute has demonstrated the ability of the antibody</p>

<p><i>and environmental sciences to provide government with scientific response to chemical and biological threats</i></p> <p>Ness Ziona, Israel</p>	<p>to neutralize the coronavirus, the antibody was specifically tested on the aggressive coronavirus.</p>
<p>Applied DNA Sciences Inc. 8</p> <p><i>The company provides molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, diagnostics and pre-clinical nucleic acid-based therapeutic drug candidates.</i></p> <p>New York, United States</p>	<p>The company has filed a provisional application with the USPTO for its diagnostic assay under development for SARS-CoV-2.</p>
<p>BriaCell⁹</p> <p><i>A bio-technology company with focus on developing novel immunotherapies to fight cancer.</i></p> <p>Vancouver, Canada</p>	<p>The biotechnology company has filed a provisional patent application with the USPTO titled, “INDUCING IMMUNE RESPONSES BY TRANSFORMING CANCER CELLS INTO ANTIGEN-PRESENTING CELLS” that covers genetically engineered whole-cell immunotherapies to infectious diseases including the SARS-CoV-2 virus that causes Covid-19. The application is based on molecular analyses of its leading anti-tumor product candidate.</p>